Officers & Directors

Officers & Directors

Email page PDF view Print view Email Alert Social media sharing

Officers & Directors

Management Team

Karen Bulock, Ph.D.
Karen Bulock, Ph.D.
Vice President Research
Karen Bulock, Ph.D. Dr. Bulock currently serves as Vice President Research for RXi Pharmaceuticals, Corporation. She joined Galena Biopharma, Inc. in October of 2007 and served as the Associate Director of Research until April 2012. Dr. Bulock has over twenty years of experience in assay development and discovery project management. Since joining RXi in 2011, and previously while at Galena, Dr. Bulock has managed several key programs, including the discovery and preclinical development of RXI-109, RXi’s first clinical candidate. Prior to joining RXi, Dr. Bulock spent several years leading assay development and screening projects to support small molecule drug discovery programs in the fields of metabolic disease and anti-infectives at CytRx Corporation and Essential Therapeutics, Inc. Dr. Bulock received a Ph.D. in Pharmacology from Yale University. Dr. Bulock has authored numerous scientific articles and is a co-inventor on four patent applications.
Gerrit Dispersyn, Dr. Med. Sc
Gerrit Dispersyn, Dr. Med. Sc
Chief Development Officer
Gerrit Dispersyn, Dr. Med. Sc Effective April 24, 2017, Dr. Gerrit Disperysn will become RXi's new Chief Development Officer. Dr. Dispersyn is an accomplished leader in clinical, product and business development. He most recently served as the Vice President, Global Head of Clinical Affairs at Integra LifeSciences Corporation. In this role, Gerrit was responsible for Integra’s global strategy and execution of Clinical Development, Clinical Operations and Medical Affairs projects and a member of Integra’s Senior Management Leadership team, and several of the company’s core teams for M&A projects. Dr. Dispersyn has also been involved in Integra’s research and business activities related to Human Cells, Tissues, and Cellular and Tissue based Products (HCT/Ps), an experience that could be beneficial for RXi’s newly added focus on immuno-oncology and cell therapy. Prior to that role, he was the Vice President, Product Development & Portfolio Management for Barrier Therapeutics, Inc., a pharmaceutical company focused on the development and commercialization of products in the field of dermatology. The company was a spin-out of Johnson & Johnson, and currently part of GlaxoSmithKline. There he led planning and implementation of all aspects of R&D operations and strategy; scientific, competitive and business intelligence; and alliance management. Dr. Dispersyn is the founder of Ingress, LLC, a consultancy company providing R&D and clinical operations support to start-up companies, supporting several pharmaceutical drug development programs. Dr. Dispersyn holds a Dr. Med. Sc. (Ph.D. in Medical Sciences), from the Faculty of Medicine, Maastricht University, Maastricht, the Netherlands, a post-graduate degree in Biomedical Imaging, and a M.Sc. in Biochemistry, both from the University of Antwerp, Belgium.
Alexey Eliseev, Ph.D.
Alexey Eliseev, Ph.D.
Chief Business Officer
Alexey Eliseev, Ph.D. Dr. Eliseev was appointed Chief Business Officer in January 2017 to spearhead the business development initiatives for the Company's immunotherapy program. Dr. Eliseev is a highly accomplished leader with over 20 years of experience in academia, biotechnology industry and venture capital and most recently was the founder and CEO of MirImmune Inc. He also co-founded Therascope, later Alantos Pharmaceuticals, with a number of prominent founders including French Nobel Laureate Jean-Marie Lehn, where he later became CTO of the company and President of its US division. Alantos was acquired by Amgen in 2007. Dr. Eliseev was also among the founders of AC Immune (Switzerland) and Boston BioCom LLC. Over recent years, he has worked with Maxwell Biotech Venture Fund as its Managing Director and ran the investment activity of the fund in the United States. Dr. Eliseev earned his PhD in Bioorganic Chemistry from Moscow State University and MBA from the MIT Sloan School of Management. Following postdoctoral research in Germany and in the US, he joined the faculty at SUNY Buffalo in 1995 where he was awarded tenure in 2000.
Pamela Pavco, Ph.D.
Pamela Pavco, Ph.D.
Chief Development Officer
Pamela Pavco, Ph.D. Dr. Pavco currently serves as Chief Development Officer for RXi Pharmaceuticals. The Company has announced that she will retire on May 19, 2017. At that time, she will continue to support the Company as part of its SAB. Dr. Pavco joined Galena Biopharma, Inc. in March of 2007 and most recently served as the Senior Vice President of Pharmaceutical Development until April 2012. Dr. Pavco has over 20 years of research and development experience in oligonucleotides. Dr. Pavco was Senior Director, Research and Development Project Management at Sirna Therapeutics, Inc., from 2002 until 2006, when it was acquired by Merck & Co., Inc. for $1.1 billion. While at Sirna, she was responsible for the discovery research and development of Sirna-027, the first chemically modified siRNA to enter clinical trials. Dr. Pavco also managed Sirna’s alliance with Allergan, Inc. that was initiated to continue discovery research in the area of ophthalmology and take Sirna-027 forward into Phase 2 clinical studies. While at Sirna, Dr. Pavco served in various additional capacities, including Director of Biology Research and Director of Pharmacology and she also managed numerous corporate collaborations and internal programs focusing on the development of therapeutic oligonucleotides in the fields of oncology, anti- angiogenesis, hepatitis, respiratory disease and Huntington’s disease. Dr. Pavco has authored numerous scientific articles and contributed to approximately 58 patents and patent applications in the oligonucleotide therapeutics field. Dr. Pavco received a Ph.D. in Biochemistry from Virginia Commonwealth University in 1983 and did her post-doctoral work at Duke University. She is a member of the American Association of Cancer Research and the Association for Research and Vision in Ophthalmology.

Board of Directors

Robert Bitterman
Robert Bitterman
Chairman
Robert Bitterman Mr. Bitterman currently serves as the President & CEO of Cutanea Life Sciences, Inc., a wholly owned subsidiary of Maruho Company, LTD., a specialty pharma development company focused on diseased and aging skin. Mr. Bitterman has over 18 years of executive leadership experience in the pharmaceutical and biologic life science industry. Prior to Cutanea, he served as President and CEO for Isolagen, Inc., an international, public, bioscience technology company where the primary proprietary platform used human fibroblasts for soft tissue enhancement. For 10 years, Mr. Bitterman served as the President and GM of Aventis’ Dermik Laboratories, a global, strategic business unit focused on therapeutic and aesthetic dermatology development and commercialization. Prior to assuming senior operational leadership positions, Mr. Bitterman held various positions of increasing responsibility in financial and commercial capacities within Aventis S.A. Mr. Bitterman holds an A.B. degree in Economics from The College of the Holy Cross and a Master of Business Administration degree from Boston University.
Keith Brownlie
Keith Brownlie
Keith Brownlie Mr. Brownlie comes to RXi after a distinguished career with Ernst & Young that spanned 36 years. During his tenure, he rapidly became one of the leading accounting specialists for life sciences companies of the greater New York area. For the last 20 years at Ernst & Young, he has held the position of Metro New York Area Life Sciences Industry Leader. Mr. Brownlie has extensive experience with SEC registration statements, initial public offerings and recurrent reporting. In his accounting career he has been involved in over 100 public offerings. Until 2010, when he retired from Ernst & Young, he was a member of Ernst & Young’s National Life Sciences Committee, and he is a member of the American Institute of CPAs. Mr. Brownlie is currently a member of the Board of Directors of Epicept and Soligenix, where in both companies he also is chairman of the Audit Committee.
Geert Cauwenbergh
Geert Cauwenbergh
Geert Cauwenbergh Dr. Cauwenbergh was appointed President and Chief Executive Officer of RXi Pharmaceuticals Corporation in April of 2012. Prior to joining RXi, Dr. Cauwenbergh served as Chairman and Chief Executive Officer of Barrier Therapeutics, Inc., a publicly-traded biopharmaceutical company he founded in 2001 that focused on dermatology drug development. Barrier was acquired by Stiefel Laboratories, Inc. in 2008. Prior to founding Barrier, Dr. Cauwenbergh held a number of ascending senior management positions at Johnson & Johnson, where he was employed for 23 years. As Vice President, Research and Development for Johnson & Johnson’s Skin Research Center, he was responsible for the worldwide research and development of all skin care products for the Johnson & Johnson consumer companies. He is a member of the board of directors of Phosphagenics and Moberg Pharmaceuticals. In 2005, Dr. Cauwenbergh was inducted into the New Jersey High-Tech Hall of Fame, and, from 2009 to 2010, he served as Chairman of the Board of Trustees of BioNJ. He has authored more than 100 publications and has been a guest editor for a number of books in mycology and infectious diseases. Dr. Cauwenbergh received his Doctorate in Medical Sciences from the Catholic University of Leuven, Faculty of Medicine (Belgium), where he also completed his masters and undergraduate work.
H. Paul Dorman
H. Paul Dorman
H. Paul Dorman Mr. Dorman brings nearly three decades of executive experience in the pharmaceutical industry with Johnson & Johnson and Baxter, in various leadership roles, to RXi. He currently serves as Chairman and CEO of DFB Pharmaceuticals, a Fort Worth, TX based holding company that, over the last 20 years, has successfully invested in and operated multiple pharmaceutical businesses. In that role, he acquired several companies, three of which were turned around to profitability, from Chapter 11 status at acquisition, and later sold to a large, multi-national, public corporation. He holds a Bachelor of Science degree in Mechanical Engineering from Tulane University and a Juris Doctor of Law from Loyola University.
Curtis Lockshin, Ph.D.
Curtis Lockshin, Ph.D.
Curtis Lockshin, Ph.D. Dr. Lockshin comes to RXi providing exceptional industry insight and functional, hands-on experience. He currently serves as the CEO of Guardum Pharmaceuticals, LLC in Lexington, MA, a wholly owned US subsidiary of OJSC Pharmsynthez which is headquartered in St. Petersburg, Russia. Prior to this role, Dr. Lockshin served as Vice President, Corporate R&D Initiatives for OPKO Health, Inc., with operational responsibilities inside several of OPKO’s R&D units. He currently serves as a Director of the Ruth K. Broad Biomedical Research Foundation, a Duke University Support Corporation. He previously served as a Director of Sorrento Therapeutics and Winston Pharmaceuticals. He initially began his career as a scientist with Sepracor and eventually became the research director responsible for the strategy and operations of Sepracor’s new leads initiative. He is a Co-Inventor on several U.S. patents and applications, covering pharmaceuticals, biomaterials, and optics for remote biochemical sensing. Dr. Lockshin holds a Ph.D. in Biological Chemistry from the Massachusetts Institute of Technology.

Scientific Advisory Board

Craig C. Mello, Ph.D.
Craig C. Mello, Ph.D.
Chairman
Craig C. Mello, Ph.D. Dr. Mello has served as the Chairman of our Scientific Advisory Board since February 2007. Dr. Mello, co-recipient of the 2006 Nobel Prize in Medicine for RNAi, co-discovered RNAi and co-invented RNAi therapeutics. Dr. Mello is the Blais University Chair in Molecular Medicine at the University of Massachusetts Medical School, a Howard Hughes Investigator and a member of the National Academy of Sciences. In 2006, he was named the inaugural recipient of The Dr. Paul Janssen Award for Biomedical Research by Johnson & Johnson and was the co-recipient of the Paul Ehrlich and Ludwig Darmstaedter Prize. Dr. Mello was also the co-recipient of the National Academy of Sciences’ Award in Molecular Biology and the Wiley Prize in the Biomedical Sciences from Rockefeller University in 2003. He was a postdoctoral fellow at the Fred Hutchinson Cancer Research Center and in 1995, was named a Pew Scholar in the Biomedical Sciences. Dr. Mello received his B.S. in Biochemistry from Brown University in 1982 and his Ph.D. in Cellular and Developmental Biology from Harvard University in 1990.
Peter Campochiaro, M.D.
Peter Campochiaro, M.D.
Peter Campochiaro, M.D. Dr. Peter Campochiaro is the George S. and Dolores Doré Eccles Professor of Ophthalmology and Neuroscience in the Johns Hopkins University School of Medicine. He is a prominent researcher, clinician and educator in the field of ophthalmology. He sees patients at the Wilmer Eye Institute at Johns Hopkins. With more than 300 articles published in peer-reviewed medical journals, Dr. Campochiaro is a clinician-scientist who does both laboratory and clinical research. His major laboratory interest is in elucidating the molecular pathogenesis of ocular neovascularization and excessive vascular leakage. He has generated many animal models of retinal and choroidal vascular diseases that have been useful for evaluating drug and gene-based therapies. His laboratory helped to demonstrate the importance of vascular endothelial growth factor (VEGF) in retinal and choroidal vascular diseases and his clinical trial group performed many of the early phase studies evaluating VEGF antagonists. He serves on Scientific Advisory Board of several pharmaceutical companies.
Jeannette Graf, M.D.
Jeannette Graf, M.D.
Jeannette Graf, M.D. Dr. Jeannette Graf is a board certified, clinical and research Dermatologist. She is an Assistant Clinical Professor of Dermatology at the Mount Sinai School of Medicine. Prior to completing her Residency in Dermatology at the New York University Medical Center, Dr. Graf earned her medical degree from the State University of New York – School of Medicine at Buffalo. Committed to research and the science of natural ingredients from an early point in her career, Dr. Graf was a research fellow and protégé of George Martin, Ph.D., lab chief and one of the most highly respected scientists in the world, at the National Institutes of Health (NIH). Dr. Graf serves as an independent consultant and advisory board member for a number of cosmetic and pharmaceutical companies including RXi Pharmaceuticals Corporation, Neutrogena, Johnson & Johnson, RoC, Allergan, Aveeno, Merz/Bioform and Medicis. She performed some of the earliest studies on soy technology used in the Aveeno product line and participated in its successful market launch. Dr. Graf also serves on the educational faculty of Allergan and Medicis, where she lectures and teaches other aesthetic physicians how to inject Botox and Restylane, and serves on the editorial board of Modern Aesthetics. She has published in prestigious journals such as Cell, Science, the Journal of Cell Biology and the Proceedings of the National Academy of Sciences. Dr. Graf has been in private practice since 1990 in Great Neck, New York.
James D. Griffin, M.D.
James D. Griffin, M.D.
James D. Griffin, M.D. James D. Griffin, MD is the Chairman, Department of Medical Oncology at the Dana-Farber Cancer Institute; Professor, Medicine at Harvard Medical School and Director, Medical Oncology at Brigham and Women's Hospital. Dr. Griffin received his medical degree from Harvard Medical School in 1974. After residency training in internal medicine at Johns Hopkins Hospital, he completed a hematology fellowship at Massachusetts General Hospital and a medical oncology fellowship at Dana-Farber. In 1981, he joined the staff of Dana-Farber, where he is chair of the Department of Medical Oncology. From 1993 to 1998, Dr. Griffin was editor-in-chief of Blood. He is a professor of Medicine at Harvard Medical School and currently sits on the scientific advisory boards of the Lombardi Cancer Center at Georgetown University and the Johns Hopkins Cancer Center and Case Western Cancer Center.
Rolf Kiessling, M.D.
Rolf Kiessling, M.D.
Rolf Kiessling, M.D. Rolf Kiessling is a Professor in Experimental Oncology at the Karolinska Institutet and Senior Chief Physician of Radiumhemmet at Karolinska Hospital. Dr. Kiessling has broad scientific expertise in the field of experimental and clinical immunology and accredited with the discovery for Natural Killer cells (NK cells) during the mid-70’s. He has published more than 250 publications in peer-reviewed journals. Professor Kiessling has served as a Member of the Research Council at the Swedish Cancer Society and the Swedish Association for Medical Research.
Leroy Young, M.D.
Leroy Young, M.D.
Leroy Young, M.D. Dr. Young is a Primary Investigator for Mercy Health Research in St. Louis, Missouri. Dr. Young is the immediate past President of the Aesthetic Surgery Education and Research Foundation (ASERF) and serves on multiple leadership committees, most recently those focused on his interests in patient safety, clinical research, emerging trends, and innovative procedures. As a member of ASERF, the American Society for Aesthetic Plastic Surgery (ASAPS), and the Plastic Surgery Educational Foundation (PSEF) he has received numerous honors, including a Distinguished Service Award from ASERF in May 2009. His clinical research activity has included trials with Botulinum Toxin Type A, Sodium and Deoxycholate injections, as well as with the antisense oligonucleotide EXC-001 for the treatment of scars and Avotermin (Juvista) for scar management. Dr. Young is a Board certified in General Surgery and Plastic Surgery. More than 150 of his articles have been published in peer-reviewed journals since 1976, and he has contributed chapters to more than 25 books. Dr. Young did his residency in general surgery at the University of Kentucky Medical Center in Lexington, and his residency in plastic surgery at the Barnes Hospital, Washington University School of Medicine, St. Louis Missouri, where he graduated in 1979.